Evidence map›Paper›PMID 39011540›Full record

ReviewFrontiers in molecular neuroscience2024

Post-translational modifications in prion diseases.

Chloé Bizingre, Clara Bianchi, Anne Baudry, Aurélie Alleaume-Butaux, Benoit Schneider, Mathéa Pietri

Abstract readReview
In one paragraph

Review in Frontiers in molecular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Therapeutic Trajectories in Human Prion Diseases.Sub-cellular biochemistry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chloé Bizingre *INSERM UMR-S 1124, Paris, France.
Clara Bianchi *INSERM UMR-S 1124, Paris, France.
Anne BaudryINSERM UMR-S 1124, Paris, France.
Aurélie Alleaume-ButauxINSERM UMR-S 1124, Paris, France.
Benoit SchneiderINSERM UMR-S 1124, Paris, France.
Mathéa PietriINSERM UMR-S 1124, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than 650 reversible and irreversible post-translational modifications (PTMs) of proteins have been listed so far. Canonical PTMs of proteins consist of the covalent addition of functional or chemical groups on target backbone amino-acids or the cleavage of the protein itself, giving rise to modified proteins with specific properties in terms of stability, solubility, cell distribution, activity, or interactions with other biomolecules. PTMs of protein contribute to cell homeostatic processes, enabling basal cell functions, allowing the cell to respond and adapt to variations of its environment, and globally maintaining the constancy of the

Indexed as

neurodegenerative diseasesPDK1 (PDPK1)PDK4phosphorylationROCKsialylationsignalingα-Secretases

Identifiers

PMID39011540
PMCPMC11247024

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.